In today's second-round match-up of The Motley Fool's Better-Buy Tournament, Gilead Sciences squares off against Berkshire Hathaway in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.
Motley Fool analyst Max Macaluso makes the case for Gilead Sciences (GILD 0.42%) to move on to the next round. Gilead is one of today's biggest biotech companies and has a number of blockbuster drugs already on the market. It also recently launched a potential blockbuster, Sovaldi, which is a new medication for the treatment of hepatitis C, and its impressive pipeline also bodes well for the company's future.
Berkshire Hathaway (BRK.A 0.97%) (BRK.B 1.24%) is managed by one of the greatest investors ever in Warren Buffett, and it should always be considered when discussing the best buys, according to Motley Fool analyst Patrick Morris. Of course, beyond its remarkable management team, there's also the reality of its diverse collection of businesses, from insurance to energy to railways and financial services.
Considering that earnings available to its shareholders of $19.5 billion in 2013 nearly doubled the $10.3 billion seen just two years ago, this is a great investment consideration.
Watch these analysts square off in the following video, and then vote for a winner. Then check out the other companies in The Motley Fool's Better-Buy Bracket.
This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Cast your vote in the poll below the video!
